Welcome to our dedicated page for Propanc Biopharma SEC filings (Ticker: PPCB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Propanc Biopharma's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Propanc Biopharma's regulatory disclosures and financial reporting.
Propanc Biopharma (PPCB) entered a Securities Purchase Agreement for a private placement of a new Series C Preferred Stock class. The deal with Hexstone Capital provides for the issuance of 100 Series C Preferred shares at closing and a Warrant to purchase up to an additional 9,900 Series C Preferred shares. Each Series C Preferred share is convertible into common stock at the lesser of a fixed $5.00 per-share conversion price or 85% of the lowest trading price during a defined period tied to a holder’s conversion notice, with a five trading day minimum. The closing is conditioned on filing the Certificate of Designation for the Series C Preferred with Delaware.
Propanc Biopharma, Inc. (PPCB) reported financials highlighting severe liquidity and solvency pressures. The company recorded an accumulated deficit of $125,621,520 and net cash used in operations of $405,168. It had no cash equivalents at June 30, 2025. Management states these conditions raise substantial doubt about the company’s ability to continue as a going concern for at least twelve months.
The filing discloses a 1:60,000 Reverse Stock Split effective January 29, 2025, numerous loans and convertible notes with defaults or past due maturities, and debt-exchange transactions that settled loans for common stock (e.g., 30,000 shares issued to settle $86,248 of loans). The company lists extensive granted patents and patent validations for its proenzyme/proenzyme compositions across many jurisdictions. It completed a registered offering that produced $3.34 million net proceeds.